Creating 600 High-Tech Jobs
RICHMOND, Va. — (October, 15 2025) — Global biopharmaceutical leader AstraZeneca has announced a $4.5 billion investment to establish two new manufacturing facilities in Albemarle County, Virginia—marking the company’s largest single manufacturing investment in history. The project is expected to create 600 high-paying jobs and generate an additional 3,000 indirect jobs, strengthening the Commonwealth’s life sciences and advanced manufacturing sectors.
The new facilities will include a drug substance manufacturing site focused on chronic diseases and an antibody-drug conjugate (ADC) facility supporting AstraZeneca’s oncology pipeline. Together, they will expand U.S. production capacity for therapies targeting cancer, obesity, heart disease, and other chronic conditions.
“This investment is a game-changer for American drug manufacturing and proof that Virginia is open for business,” said Governor Glenn Youngkin. “AstraZeneca will create hundreds of high-quality jobs and advance lifesaving innovation right here in the Commonwealth.”
AstraZeneca CEO Pascal Soriot added, “With our $4.5 billion investment in Virginia—the largest in our company’s history—we are building a state-of-the-art manufacturing facility that will drive innovation, strengthen health security, and fuel economic growth across the U.S.”
The project will be located at the Rivanna Futures Site in northern Albemarle County, previously awarded a $9.7 million Virginia Business Ready Sites Program grant to prepare the property for major industrial development. AstraZeneca’s expansion was secured through collaboration between the Virginia Economic Development Partnership (VEDP), Albemarle County, and the Major Employment and Investment (MEI) Project Approval Commission.
Support for workforce development will be provided through the Virginia Talent Accelerator Program, the nation’s top-ranked customized training initiative, ensuring AstraZeneca can begin operations swiftly with a skilled local workforce.
AstraZeneca’s U.S. footprint includes 19 research, manufacturing, and commercial sites employing more than 18,000 people. This latest expansion underscores Virginia’s growing role as a hub for biotech innovation, life sciences manufacturing, and high-skill job creation.
For more information, visit www.astrazeneca.com.
